One Trial Plus Confirmatory Evidence: FDA's 2026 Substantial Evidence Draft Explained

When a drug sponsor plans a development programme, one question shapes the budget, the timeline and the risk profile more than almost any other: how much clinical evidence will the regulator require before it will approve the product? For decades the working assumption in the United States was two adequate and well-controlled trials. On 24 June 2026, the U.S. Food and Drug Administration reissued a revised draft guidance that reframes that assumption for the modern evidence landscape.

The guidance, titled Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products, clarifies when a single adequate and well-controlled clinical investigation, supported by confirmatory evidence, can satisfy the statutory effectiveness standard. Comments close on 22 September 2026. For Canadian sponsors who file in both the United States and Canada, this is more than an American technicality. It changes how evidence packages should be planned, and it interacts directly with Health Canada pathways such as the New Drug Submission and the Notice of Compliance with Conditions.

Executive Summary

The revised draft does not lower the effectiveness bar. It clarifies how sponsors can meet it more efficiently, and it puts confirmatory evidence at the centre of that discussion.

• The revised draft guidance (Docket FDA-2019-D-4964, 91 FR 37994) confirms that one adequate and well-controlled trial plus confirmatory evidence can meet the substantial evidence of effectiveness standard under section 505(d) of the Federal Food, Drug, and Cosmetic Act.
• It removes older language that described one trial as the legal and scientific equivalent of two trials, and stresses that sponsors relying on a single trial must provide confirmatory evidence.
• The amount and quality of confirmatory evidence should scale with the strength of the single trial. A weaker single trial demands stronger confirmatory support.
• When finalised, the guidance will replace FDA's 1998 guidance on providing clinical evidence of effectiveness.
• Comments are due 22 September 2026, so sponsors have a short window to shape the final version.
• Canadian sponsors should map their US evidence strategy onto Health Canada requirements early, because the two systems weigh the same data differently.

What Is Substantial Evidence of Effectiveness?

In short: substantial evidence of effectiveness is the legal standard a drug or biologic must meet before FDA will approve it as effective. It comes from adequate and well-controlled clinical investigations from which qualified experts can conclude that the drug will have the effect its labelling claims. The standard is set in section 505(d) of the Federal Food, Drug, and Cosmetic Act.

Why it matters: the number and type of studies FDA expects drives the cost and length of a development programme. A programme built around two large confirmatory trials can cost far more, and take years longer, than one built around a single well-designed trial supported by other credible evidence. Getting the evidence strategy right early is one of the highest-leverage decisions a sponsor makes.

What to do: decide, before the pivotal trial is designed, whether the programme will rely on one trial plus confirmatory evidence or on more than one trial. That decision affects trial size, endpoint selection, the biomarker and mechanistic work you fund, and the meetings you request with the agency. It is far cheaper to plan the confirmatory-evidence package up front than to assemble it after a single trial reads out.

What Changed in the 2026 Draft Guidance

In short: the statutory standard has not moved. What FDA has done is modernise how it explains the standard, and tie the strength of the confirmatory evidence to the strength of the single trial.

The idea that one trial plus confirmatory evidence can satisfy the standard is not new. It was written into statute by the Food and Drug Administration Modernization Act of 1997 and explained in FDA's 1998 guidance. The 2026 draft is the latest step in a long line of documents that refine, rather than rewrite, that principle. The table below traces the lineage.

The most practically important change is the removal of language that treated a single trial as the legal and scientific equivalent of two trials. FDA found that framing caused confusion. The revised draft is blunt: a sponsor relying on one adequate and well-controlled clinical investigation must provide confirmatory evidence, and how much is needed depends on how persuasive the single trial is.

One Adequate and Well-Controlled Trial, Plus Confirmatory Evidence

In short: the single trial still has to be a genuinely adequate and well-controlled study. Confirmatory evidence supports that trial, it does not replace it.

FDA's regulations at 21 CFR 314.126 describe the features of an adequate and well-controlled study. A single trial that carries the weight of a marketing application should show these characteristics:

• A clear statement of objectives and a design that permits a valid comparison with a control.
• A method of assigning patients that minimises bias, usually randomisation, with blinding where feasible.
• A well-defined and reliably measured endpoint that reflects a clinically meaningful benefit.
• A study population defined tightly enough that the result can be interpreted and generalised.
• A pre-specified analysis adequate to assess the drug's effect and to rule out chance as a likely explanation.

Confirmatory evidence is the additional information that, together with the single trial, gives the agency confidence that the finding is real and reproducible. It is the bridge between one positive study and the reassurance that a second study would have provided.

What Counts as Confirmatory Evidence

In short: confirmatory evidence is credible scientific support drawn from outside the single pivotal trial. FDA's guidance describes several recognised categories, summarised below.

No single category is mandatory. A sponsor selects the sources that fit the molecule, the disease and the trial, and it should discuss the proposed package with FDA before locking the design. The categories FDA has identified include the following.

The revised draft ties these sources together with a clear expectation: a single-trial programme should rest on either a highly persuasive trial or a source of strong confirmatory evidence. In general, the weaker or more uncertain the single trial, the stronger the confirmatory evidence must be. A large, highly persuasive trial in a well-understood disease may need only modest confirmation, while a smaller or more novel trial will need more.

Regulatory Flexibility for Rare Diseases and Unmet Need

In short: FDA retains flexibility for serious diseases that lack effective treatment, where the cost of delaying a real therapy can outweigh some added uncertainty about effect.

This flexibility is most visible in rare diseases, paediatric subsets, and first-in-class therapies for conditions with no good options. The draft is clear that flexibility is not a lower standard, it is a recognition that somewhat greater uncertainty may be acceptable in critical settings when weighed against the risk of withholding an effective drug. Sponsors in these areas should use FDA meetings, including the various formal meeting types, to agree on how much evidence will be enough before they commit to a design.

The Canada Bridge: Mapping a US Strategy onto Health Canada

In short: Health Canada also requires substantial clinical evidence for a New Drug Submission, but it assesses the totality of the evidence under its own regulations. A single-trial strategy that satisfies FDA is not automatically sufficient in Canada, and vice versa.

Under the Food and Drug Regulations, a New Drug Submission must include substantial evidence of the clinical effectiveness of the drug for its recommended use, a requirement set out in section C.08.002(2)(h). Health Canada does not publish a one-trial-plus-confirmatory-evidence guidance identical to FDA's, and it reviews each submission on the strength of the whole data package. A sponsor that plans a lean US programme should confirm, early, that the same package will support a Canadian filing, or plan the bridging evidence it will add.

Where the evidence is promising but not yet complete, Canada offers a conditional route. The Notice of Compliance with Conditions pathway lets Health Canada authorise a serious-disease product on the basis of promising evidence, on the condition that the sponsor completes confirmatory studies after approval. That structure mirrors the logic of confirmatory evidence and is a natural home for single-trial programmes crossing the border. Sponsors should also align their trial transparency obligations, including Canadian clinical trial disclosure requirements, with their US plans from the outset.

Compliance and Strategy Checklist

Use this checklist to pressure-test a single-trial development programme before you commit to it.

• Decide the evidence approach (one trial plus confirmatory evidence, or more than one trial) before the pivotal trial is designed.
• Confirm the single trial meets every feature of an adequate and well-controlled study, not just statistical significance.
• Name the specific confirmatory-evidence sources you will rely on, and generate them on purpose rather than hoping they emerge.
• Match the strength of the confirmatory package to the strength of the trial. Plan more support for smaller or novel trials.
• Request a formal FDA meeting to align on the evidence package before the pivotal trial starts, and document the agreement.
• Map the same evidence package onto the Health Canada New Drug Submission and, where relevant, the Notice of Compliance with Conditions pathway.
• Keep contemporaneous documentation and a clean audit trail for all supporting data, including real-world and registry sources, so the package survives inspection.
• Consider filing a comment to Docket FDA-2019-D-4964 by 22 September 2026 if the draft affects your programme.

Common Mistakes to Avoid

• Treating one trial as automatically sufficient. The draft removes exactly this assumption. A single trial without pre-planned confirmatory evidence is a common route to a complete response letter.
• Assembling confirmatory evidence after the fact. Evidence gathered as an afterthought is weaker and less credible than evidence generated by design. Plan it into the programme.
• Assuming FDA and Health Canada will read the same package the same way. They apply different regulations and can reach different conclusions on identical data. Plan both filings together.
• Using low-quality real-world data. Registry and real-world evidence only helps if the data quality, provenance and analysis are defensible. Poorly governed data undermines rather than supports the case.
• Skipping the FDA meeting. The most expensive way to learn that your evidence is insufficient is at the review stage. Agree the standard in advance.

Frequently Asked Questions

Does the 2026 draft mean the FDA now approves drugs on a single trial?

Not on its own. The draft clarifies that a single adequate and well-controlled trial can support approval only when it is paired with confirmatory evidence. The single trial still has to be rigorous, and the confirmatory evidence has to be credible. This principle has existed in US law since 1997, and the draft explains how to apply it, it does not create a new shortcut.

What is the difference between confirmatory evidence and a second trial?

A second adequate and well-controlled trial is one specific way to confirm a finding. Confirmatory evidence is a broader set of options, including mechanistic data, natural history, related-indication results, same-class experience and real-world data. The draft lets sponsors choose the confirmatory approach that best fits the science, provided it is strong enough for the trial it supports.

When is the comment deadline, and how do I submit?

Comments are due 22 September 2026. You can submit electronically through regulations.gov under Docket No. FDA-2019-D-4964, or by written submission to FDA's Dockets Management Staff. Confidential business information should be filed as a written submission following FDA's instructions rather than posted publicly.

How does this affect rare disease programmes?

Rare disease programmes benefit most, because a two-trial requirement is often impractical when patients are few. The draft preserves regulatory flexibility for serious diseases that lack treatment, and natural history data is a particularly useful form of confirmatory evidence in progressive rare conditions. Sponsors should still align with FDA on exactly what will be sufficient.

Will Health Canada accept a single-trial submission that satisfied the FDA?

Possibly, but it is not automatic. Health Canada assesses a New Drug Submission on the totality of the evidence under the Food and Drug Regulations, and it can reach a different conclusion than FDA on the same data. For promising but incomplete evidence, the Notice of Compliance with Conditions pathway may allow conditional approval with confirmatory studies to follow. Plan the Canadian filing alongside the US one rather than after it.

Does the draft guidance replace earlier documents?

When finalised, it will replace FDA's 1998 guidance on providing clinical evidence of effectiveness. Until it is final, the draft represents FDA's current thinking and is not binding. FDA has also said it will consider comments on the separate 2023 draft on the same subject when deciding on future action.

How MFLRC Can Help

MF License and Regulatory Consultants (MFLRC) helps drug and biologic sponsors turn evidence strategy into an approvable submission. Our regulatory affairs, licensing and submissions team pressure-tests single-trial programmes, designs the confirmatory-evidence package, prepares briefing documents for FDA meetings, and drafts comment letters on open dockets like this one. Because we work across both Health Canada and FDA frameworks, we build the Canadian bridge into the plan from day one.

We also support gap assessments of existing data packages, evidence-strategy memos, pre-submission meeting preparation, and Canada-US bridging strategy for New Drug Submissions and the Notice of Compliance with Conditions pathway. If your programme touches generics, our guide to the ANDA and 505(b)(2) pathways is a useful companion. The goal is simple: know what evidence the agency will require before you spend years generating the wrong package.

Conclusion

FDA's 2026 revised draft does not lower the effectiveness bar, it modernises how sponsors clear it. The message for anyone planning a development programme is to decide the evidence strategy early, treat confirmatory evidence as a designed part of the plan rather than a late addition, and match the strength of that evidence to the strength of the single trial. For sponsors filing in both countries, the same discipline applied to the Health Canada New Drug Submission and the Notice of Compliance with Conditions pathway avoids expensive surprises. The comment window closes 22 September 2026, and it is a rare chance to shape the standard you will have to meet.

Sources and References

• Federal Register, Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products; Revised Draft Guidance (91 FR 37994, 24 June 2026)
• FDA, Guidances for Drugs (search and access the draft guidance document)
• Electronic Code of Federal Regulations, 21 CFR 314.126, Adequate and well-controlled studies
• Regulations.gov, Docket FDA-2019-D-4964 (submit comments by 22 September 2026)
• Health Canada, Notice of Compliance with Conditions (NOC/c) policy and guidance